QM · rank #15 · 2026-07-27
SNT
GPW · PLN · $814M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +47.73% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $814M |
| Anchor (recent) Close on 2026-06-26 | $320.60 |
| Anchor (far) Close on 2025-06-27 | $217.02 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
SNT@GPW (Synektik S.A.) is a Polish medical devices and nuclear medicine group that supplies radiology/PACS systems and manufactures PET radiopharmaceuticals.
Rationale
The screen fits a quality-momentum profile because SNT shows strong 12-1 momentum, very high ROE, solid margins, and a mid-cap size that can re-rate on earnings surprises like the reported H1 FY2025/26 profit jump.
Material risks
- 1A meaningful part of the recent net profit surge came from the 93CH separation/carve-out rather than purely organic operating improvement, so earnings quality and repeatability need confirmation.
- 2Synektik remains exposed to Polish public-hospital procurement and regulatory/safety risk in PET radiopharmaceutical production, which can create volatility in revenue and margins.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.